VPS35 is the core scaffolding component of the retromer complex, a multimeric protein machinery that mediates selective retrieval of transmembrane cargo from endosomes back to the trans-Golgi network (TGN) or plasma membrane[@seaman2012]. As the largest retromer subunit, VPS35 provides the structural framework for cargo recognition and coordinates the recruitment of accessory proteins that drive vesicle formation and trafficking[@bhalla2012].
VPS35 is the core scaffolding component of the retromer complex, a multimeric protein machinery that mediates selective retrieval of transmembrane cargo from endosomes back to the trans-Golgi network (TGN) or plasma membrane[@seaman2012]. As the largest retromer subunit, VPS35 provides the structural framework for cargo recognition and coordinates the recruitment of accessory proteins that drive vesicle formation and trafficking[@bhalla2012].
Mutations in VPS35 are linked to autosomal dominant late-onset Parkinson's disease, making it one of the rarer monogenic PD genes with clear mechanistic relevance to sporadic disease[@zimprich2011].
Pathway Diagram
Mermaid diagram (expand to render)
Structure
VPS35 is a 796-amino acid protein that forms a stable heterotrimeric complex with VPS26 and VPS29. The structure consists of:
N-terminal beta-propeller domain: Mediates interaction with VPS26
C-terminal alpha-helical domain: Binds to cargo recognition proteins
Coat Assembly: Recruits dynamin and other proteins to form trafficking vesicles
Transport: Facilitates movement of cargo from endosomes to the TGN or plasma membrane
Key Neurodegeneration-Relevant Cargo
VPS35/retromer traffics several proteins central to neurodegenerative disease:
APP: [Amyloid precursor protein](/proteins/app-protein) trafficking is regulated by retromer; impaired retrieval leads to amyloidogenic processing[@moceri2021]
[Tau](/proteins/tau): Retromer regulates tau secretion and may influence tau spreading through the extracellular space
Alpha-synuclein: Retromer dysfunction may contribute to [alpha-synuclein](/proteins/alpha-synuclein) accumulation and Lewy body formation
GBA1: Glucocerebrosidase trafficking to lysosomes is retromer-dependent; GBA1 mutations increase PD risk synergistically with VPS35 dysfunction
Wntless: Wnt protein secretion requires retromer-mediated retrieval
Role in Parkinson's Disease
VPS35 D620N Mutation
The most well-characterized VPS35 mutation is D620N (asparagine at position 620 substituted for aspartate), which causes autosomal dominant late-onset Parkinson's disease[@zimprich2011]. This mutation:
Incompletely penetrant: Estimated 30-60% lifetime risk of PD
Age of onset: Typically 50-60 years
Phenotype: Similar to sporadic PD with typical Lewy body pathology
Mechanism of Pathogenesis
The D620N mutation affects retromer function through several mechanisms[@tang2020]:
Impaired cargo sorting: Reduced ability to recognize and sort specific cargo proteins
Accumulation of toxic proteins: Impaired trafficking of neurodegeneration-related proteins
Synaptic dysfunction: Disrupted synaptic vesicle recycling at nerve terminals
Interaction with Other PD Genes
VPS35 intersects with several major Parkinson's disease genes:
GBA1: Retromer regulates GBA1 trafficking to lysosomes; GBA1 mutations increase PD risk and may synergize with VPS35 dysfunction
LRRK2: [LRRK2](/proteins/lrrk2-protein) phosphorylates retromer components including VPS35, regulating trafficking efficiency
PINK1/Parkin: The mitophagy pathway intersects with endosomal trafficking; VPS35 dysfunction may impair clearance of damaged mitochondria
Retromer Dysfunction in Non-Mutant PD
Even without VPS35 mutations, retromer function declines with age and is impaired in sporadic Parkinson's disease[@vps35review2023]. This age-related decline may:
Reduce clearance of alpha-synuclein aggregates
Impair lysosomal delivery of GBA1
Disrupt autophagy-lysosome pathways
Contribute to endosomal trafficking defects observed in PD patient neurons
Therapeutic Targeting
Small Molecule Enhancers
Retromer function can be enhanced pharmacologically:
Retromer stabilizers: Small molecules that stabilize the retromer-cargo complex and compensate for mutant VPS35
Pharmacological chaperones: Compounds that improve trafficking of mutant proteins through the endosomal system
Gene therapy: Viral vector delivery of wild-type VPS35 to restore retromer function
Drug Development Landscape
Several strategies are being explored:
Antisense oligonucleotides: Reduce toxic protein accumulation by modulating expression
Protein-protein interaction modulators: Compounds that enhance retromer assembly or cargo binding
Endosomal maturation enhancers: Promote the transition from early to late endosomes to improve cargo routing